Sarepta Therapeutics | search
Click here to view Sarepta Therapeutics news from 60+ newspapers.
Bookmark or Share- In a first, FDA approves Sarepta gene therapy for Duchenne muscular ...The company that developed the treatment, Sarepta Therapeutics of Cambridge, Mass., said the therapy would be available as soon as possible. The treatment, called Elevidys, will cost $3.2...
- Sarepta Therapeutics | Biopharmaceutical Company for Rare DiseasesSarepta is engineering solutions for rare diseases with science that is on the forefront of precision genetic medicine. Our platforms include: gene therapy, RNA technologies, and gene editing. We are in a daily race to save lives stolen or impacted by rare disease.
- Sarepta Therapeutics Announces FDA Approval of ELEVIDYS, the First Gene ...CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 22, 2023-- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), the leader in precision genetic medicine for rare diseases, today announced U.S. Food and Drug Administration (FDA) accelerated approval of ELEVIDYS (delandistrogene moxeparvovec-rokl), an adeno-associated virus based gene therapy for the treatment of ...
- About Our Company | Sarepta TherapeuticsSarepta is a global biotechnology company on an urgent mission: to engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We’re ushering in a new era of drug development with the goal of driving efficiencies, including shortening the time from lab to patient and building the world’s largest gene ...
- News & Press Releases | Sarepta TherapeuticsRead news and articles from Sarepta, a global biotechnology company developing potentially life-changing precision genetic medicine.
More
